As of 2 Nov 2026, Hamps Bio is loss-making on a trailing 12-month basis, with a net loss of ₹0.74 Cr, so it has no P/E ratio. The share price is ₹25.50. Sales grew 14% a year over 3 years. Debt is 0.85× equity. It is a small-cap company with a market cap of ₹22 Cr; the shares fell 1.9% over the past year.
- ₹25.95
- ₹25.95
- ₹25.50
- ₹25.50
- 12K
Health check
- ReturnsModest
−1.9% over the past year.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +13.7% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -3.8%.
- Balance sheetStretched
Debt 0.85× equity, interest covered 0.6×.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹22 Cr
- Small cap
- P/E
- n/a
- Price to book
- 2.74
- Book value ₹9.30
- Dividend yield
- 0.00%
- ROE
- −8.7%
- Return on equity
- ROCE
- −3.8%
- Return on capital employed
- Debt to equity
- 0.85
- Debt ₹6.88 Cr
- EPS (TTM)
- −₹0.85
- OPM (TTM)
- −8.8%
- Net margin −8.7%
- Sales growth
- +43.3%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 2.62
- EV/EBITDA 98.6
Strengths and risks
Strengths
- Quarterly sales up 43.3% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −8.7%.
- Interest coverage of only 0.6×.
About Hamps Bio
Hamps Bio Limited engages in marketing and manufacturing of pharmaceutical, freeze-dried food, and nutraceutical ingredients in India and internationally. It operates through Pharma Products and Freeze-Dried Products segments. The company offers nutrition supplements, injection, pediatric care, toothpaste, mouth wash, antiacid/PPI, painkiller/anti-inflammatory, hematantic/calcium supplement, and antibiotic/antibacterial/antifungal pharmaceutical products.…
- Headquarters
- Surat
- Employees
- 51
- Sector
- Healthcare
- ISIN
- INE0QBD01018
- Website
- hampsbio.com
Price range
- Avg volume (3M)
- 5K
- 1-year return
- minus 1.9%
- From 52-week high
- minus 4.1%
Peers
We couldn’t find listed peers for this company.
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- +13.7%
- ROE
- −8.7%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 4.9 | 5.9 | 6.3 | 7.3 | |
| – | +20.3% | +5.6% | +15.7% | |
| 4.1 | 4.7 | 5.4 | 7.1 | |
| 0.9 | 1.2 | 0.9 | 0.1 | |
| 17.5% | 20.8% | 13.6% | 1.8% | |
| −0 | 0 | 0 | 0.3 | |
| 0.2 | 0.1 | 0.1 | 0.2 | |
| 0.3 | 0.4 | 0.4 | 0.8 | |
| 0 | −0.1 | – | −0.1 | |
| 0.4 | 0.6 | 0.4 | −0.7 | |
| −0.5% | 23.0% | 26.3% | −5.5% | |
| 0.4 | 0.5 | 0.3 | −0.7 | |
| – | +39.4% | minus 40.5% | minus 348.1% | |
| 0.41 | 0.57 | 0.34 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1.5 | 2 | 4.4 | 8.7 | |
| −0.1 | 1.4 | 4.4 | −0.6 | |
| 1.7 | 1 | 3 | 6.9 | |
| 0.9 | 0.7 | 1 | 0.9 | |
| 4 | 5.1 | 12.8 | 15.9 | |
| 2.6 | 2.5 | 6.8 | 9 | |
| – | – | 3.3 | 1.1 | |
| 0 | 0 | 0 | 0 | |
| 0 | 0.1 | 0.1 | 0.2 | |
| 1.3 | 2.5 | 2.7 | 5.6 | |
| 4 | 5.1 | 12.8 | 15.9 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1.2 | −0.3 | −1.8 | −0.8 | |
| −0.7 | −0.4 | −6.2 | −2.9 | |
| −0.5 | 0.7 | 8 | 3.7 | |
| −0 | 0 | 0 | 0.1 | |
| −0.8 | −0.4 | −3.7 | −5.1 | |
| 0.4 | −0.7 | −5.5 | −5.9 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.